Improving Retreatment Success (IMPRESS)

Inclusion Criteria: * Adults ≥ 18 years of age * Previous history of anti-TB chemotherapy * HIV status: HIV infected and uninfected patients are allowed in the study: * All patients must agree to HIV testing to confirm HIV status. * Patients already on ARVs will be allowed in the study provided that the ART regimen is not contraindicated with any of the study agents . * HIV infected patients at any CD4 count irrespective of ART commencement and duration will be included in the study * Smear positive or Gene Xpert positive pulmonary tuberculosis * Rifampicin susceptible as determined by Gene Xpert at screening. Gene Xpert will be used to determine rifampicin resistance, hence the study team will made aware of resistance within 48 hours and prior to study enrolment. * Karnofsky score greater than 70 * Female candidates of reproductive potential must agree to use two reliable methods of contraception while on study: a barrier method of contraception (condoms or cervical cap) together with another reliable form of contraceptive (condoms with a spermicidal agent, a diaphragm or cervical cap with spermicide, an Intrauterine Device (IUD), or hormone-based contraceptive) * A negative pregnancy test * Laboratory parameters done at, or 14 days prior to, screening: * Haemoglobin level of at least 7.0 g/dL * Serum aspartate transaminase (AST) and alanine transaminase (ALT) activity less than 3 times the upper limit of normal * Serum total bilirubin level less than 2.5 times upper…